This filing contains no material financial data or operational changes. The CEO's health disclosure and CAO departure are routine personnel events. Monitor upcoming quarterly earnings for any operational impact from the CEO's reduced travel, but no immediate trading action is warranted.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 18 $77.79entry
- T+1 · 6mo ago −0.76%α −0.11% · $77.20
- T+5 · 6mo ago +3.41%α +1.79% · $80.44
- T+20 · 5mo ago +4.57%α +2.38% · $81.35
- T+60 · 3mo ago −5.21%α −9.79% · $73.74
Price Chart
How similar events traded
Executive Summary
CEO Geoff Ballotti disclosed a multiple myeloma diagnosis with a favorable prognosis, stating he will continue working largely as normal. Separately, CAO Nicola Rossi will depart on July 31, 2026, with internal successor Christopher Androski named. The 2026 annual meeting results were also filed, showing all director nominees elected and say-on-pay approved with ~85% support. Neither event provides material new financial information or changes the company's operational outlook.
Key Facts
- CEO Geoff Ballotti diagnosed with multiple myeloma, a treatable form of bone cancer; prognosis is favorable and he plans to continue working largely as normal.
- Chief Accounting Officer Nicola Rossi will depart on July 31, 2026; Christopher Androski (current SVP & Controller) will succeed him.
- 2026 Annual Meeting held May 14, 2026: all 9 director nominees elected; say-on-pay approved with ~85% of votes cast in favor; auditor ratification passed with ~99% support; stockholder written consent proposal passed with ~63% support.
- No financial figures, guidance changes, or material operational updates were disclosed in this filing.
Financial Impact
No financial impact disclosed. CEO health disclosure and CAO transition are personnel matters without quantifiable financial exposure.
Risk Factors
- CEO's health condition could worsen despite favorable prognosis, potentially creating leadership uncertainty.
- CAO transition may introduce minor accounting process risk during the handoff period.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-021771 |
| Document: ef20073914_ex99-1.htm | 0001140361-26-021771 |
| Document: 0001140361-26-021771-index-headers.html | 0001140361-26-021771 |
| Document: 0001140361-26-021771-index.html | 0001140361-26-021771 |
| Document: 0001140361-26-021771.txt | 0001140361-26-021771 |
Track record
20 reports on WH
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $79.19 Now $80.36 +1.48% settles Nov 23
- Nov 12, 20264d ago Press Release Neutral 2/10 Entry $79.32 Now $80.36 +1.31% settles Nov 20
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $81.12 Now $80.36 −0.94% settles Nov 17
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $77.83 to $78.93 Now $80.36 +3.25% ▲ +1.41% −1.88% vs SPY
- Nov 3, 202613d ago Institutional Cluster Mixed 3/10 Entry $79.08 to $81.12 Now $80.36 +1.62% ▲ +2.58% +3.17% vs SPY
- Oct 21, 202626d ago 8-K Bullish 6/10 No price data
- Oct 21, 202626d ago Press Release Bullish 6/10 Entry $75.07 to $76.93 Now $80.36 +7.05% ▲ +2.48% +1.77% vs SPY
- Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.07 to $76.93 Now $80.36 +7.05% ▲ +2.48% +1.77% vs SPY
- Oct 15, 20264w ago 144 Neutral 2/10 Entry $75.60 to $72.42 Now $80.36 +6.30% ▼ −4.21% −4.30% vs SPY
- Sep 29, 20266w ago Press Release Neutral 3/10 Entry $72.44 to $72.65 Now $80.36 +10.93% ▲ +0.29% −1.66% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers